The Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Biomarkers of Aging in Older Overweight/Obese Adults With Insulin Resistance
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Lean Body Mass Change
Study Overview
Brief Summary
Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Basic Science
- Masking
- None
Eligibility Criteria
- Ages
- 65 Years to 90 Years (Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Older than 65
- •Have prediabetes or diabetes
- •BMI ≥ 27.0 kg/m2
- •Living independently (not in assisted living or nursing home)
Exclusion Criteria
- •Have heart disease
- •Have liver disease
Arms & Interventions
Semaglutide and lifestyle intervention
Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program. They will also be given semaglutide for 20 weeks.
Intervention: Semaglutide Injectable Product (Drug)
Semaglutide and lifestyle intervention
Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program. They will also be given semaglutide for 20 weeks.
Intervention: Lifestyle Counseling (Behavioral)
Lifestyle intervention
Participants will meet with a dietician throughout the study to discuss lifestyle counseling based on recommendation in the diabetes prevention program
Intervention: Lifestyle Counseling (Behavioral)
Outcomes
Primary Outcomes
Lean Body Mass Change
Time Frame: Baseline to 20 weeks
Determine if there is any change in lean body mass
Secondary Outcomes
No secondary outcomes reported
Investigators
Tiffany Cortes
Assistant Professor
The University of Texas Health Science Center at San Antonio